Hutchison China MediTech
Hong Kong, China

Hutchison China MediTech (Chi-Med), a Hong Kong-based biopharmaceutical company, is on track to become a global leader in the discovery, development, and commercialisation of innovative, highly selective oral tyrosine kinase inhibitor therapies for oncology and immunological indications.

Investment Perspective

2020 is set to be the breakthrough year as Hutchison China MediTech (‘Chi-Med’) consolidates its position as a world-class innovator and developer of best-/first-in-class small molecule tyrosine kinase inhibitors (TKIs). The company’s phenomenal journey since inception twenty years ago means it is well-positioned to capitalise on its recent progress. Chi-Med has exploited its early-mover advantage in China to build a broad and innovative TKI pipeline and a credible domestic commercial presence, which provides the foundation for the future commercialisation of its China Oncology pipeline. It is preparing for a first in-house China launch in H220 and filing of two further China NDAs in 2020. Alongside, Chi-Med has established a US clinical and regulatory presence which is supporting imminent Global Innovation pivotal trial initiations and should clarify timing of first US/EU filing in the near-term. Ahead of these important catalysts, we value Chi-Med at £5.08/share or $32.99/ADS.

Market information



AACR 2020: first surufatinib/PD-1 combo data
Update | 30 Apr 2020
Weathering the COVID-19 storm
Update | 20 Apr 2020
Laying the foundations for a new era
Outlook | 20 Apr 2020

Recent News

Clinical Collaboration with Beigene
26 May 2020
Clinical data to be presented at ASCO 2020
14 May 2020
Surufatinib presentations at upcoming AACR virtual annual meetings
22 Apr 2020
Surufatinib granted FDA Fast Track Designations for NETs
17 Apr 2020